LifeMine Therapeutics raised $263 million across two venture rounds to support what it says could be a safer, more convenient immunosuppressant for transplant patients. Led by serial biotech entrepreneur Greg Verdine, the financing includes a previously unannounced $75 million Series D and is aimed at advancing a lead program in clinical settings. In parallel, Vedanta Biosciences secured $60 million to push a Phase 3 program for its C. difficile microbiome therapy, targeting a readout next year. The funding signals continued investor appetite for microbiome approaches in infectious disease where clinical validation and manufacturing scalability remain key risks. The combined moves reinforce how specialty biotechs are funding late-stage execution by pairing platform-led discovery narratives with near-term clinical milestones to de-risk development and preserve cash runway.